The admission by UN's lead agency for drugs, the UNODC, that “the drug market is thriving” in its 2017 World Drug Report is an important one given that it is months away from 2019 – the target date by which governments committed to “significantly reduce or eliminate” the global drug market. At the recent annual gathering of the Commission on Narcotic Drugs (CND) in Vienna, this abysmal failure to claim any progress towards these ‘drug-free’ targets was the backdrop to the latest round of tense negotiations on global drug control.
The recent publication of two single pieces of legislation - the amended 1993 Narcotic Drugs and Psychotropic Substances Law and the first National Drug Control Policy - is likely to form the basis of Myanmar’s drug policy for several years to come. What does it mean for the country’s transition towards an evidence-based approach to drug control, and how can the gaps between the two documents be addressed?
Martin Jelsma, Neil Boister, David Bewley-Taylor, Malgosia Fitzmaurice, John Walsh
15 March 2018
Legal tensions are growing within the international drug control regime as increasing numbers of member states move towards or seriously consider legal regulation of the cannabis market for non-medical purposes. Amongst reform options not requiring consensus, inter se modification appears to be the most ‘elegant’ approach and one that provides a useful safety valve for collective action to adjust a treaty regime arguably frozen in time.
As a growing number of countries move towards legal regulation for non-medical cannabis, governments are pushing the boundaries of the three UN drug control treaties. At the 61st session of the Commission on Narcotic Drugs (CND), TNI will co-organise a side event to explore the issue, addressing the various challenges and opportunities involved.
After decades of relative tolerance towards Cannabis in Spain, the Constitutional Court decides that cannabis clubs are criminal. Years of government criminalizing strategy pay off. The national parliamentary debate can no longer be postponed.
A draft bill amending Myanmar 1993 Narcotic Drugs and Psychotropic Substances Law was published in newspapers in March 2017 for public consultation. It was subsequently discussed in the upper house of Parliament (Amyothar Hluttaw) on 16 August 2017.
Between 10 and 25 June 2017, the Transnational Institute organised a Southeast Asian advocacy fellowship programme on drug policy reform, attended by seven participants from Thailand, Cambodia, the Philippines, Indonesia, and Myanmar. One of the participants, Viona Wijaya from Indonesia, shares her experiences in this article.
Myanmar is better known for its serious drug problems - including large-scale illicit drugs production and trafficking and high rates of heroin use - than for implementing progressive drug policies that prioritise the health of its population. However, this could change in the near future.
The Economist - In much of the Middle East and north Africa, where the law often lumps pot in with harder drugs, possession of a single joint can lead to jail. But some governments are acknowledging the harmful effects of their policies and thinking about reform.
We are calling for applications from those working in sectors related to drug policy in order to increase their understanding of international drug policy reform issues, to improve their advocacy skills, and to enhance their capacity in working with the media on drug policy.
Cannabis (or marihuana) is one of the most widely consumed psychoactive substances in the world. According to the United Nations World Drug Report, 183 million people, or 3.8% of the world’s population, used cannabis in 2014. Its cultivation was also reported by 129 countries. Cannabis is subject to the United Nations System for International Control of Narcotic Drugs and Psychotropic Substances (hereafter “drugs”) and is the most widely consumed of all the drugs. According to that control system, cannabis is among the substances with the strictest legal status; they are the most prohibited, supposedly because of the harm they cause and their lack of medical usefulness.
Paraguay is the principal producer of cannabis in South America. Despite its importance as a supplier of cannabis in South America, there has been a surprising absence of serious studies of its impact on its own society, and on the play of offer and demand in neighbouring countries.
As an increasing number of jurisdictions consider whether and how to legalize and regulate access to cannabis, tensions are growing between these initiatives and countries’ obligations under the UN drug control conventions. A groundbreaking new report produced by a coalition of legal and drug policy experts offers strategies for countries exploring regulatory approaches to cannabis to do so in ways that ensure that their domestic reforms align with their international legal obligations.